Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App




Low Levels of 1-Asparaginase Predict Cancer Recurrence

By LabMedica International staff writers
Posted on 08 May 2017
Loss of expression of the enzyme ASRGL1 (l-asparaginase) was shown to be an independent biomarker for disease-specific survival in uterine cancer (endometrioid endometrial carcinoma).

Endometrial cancer of the uterus is the most common form of gynecologic cancer in Europe and North America. More...
The treatment primarily consists of removing the uterus with follow-up chemotherapy in cases where the risk of recurrence is deemed high. Investigators at Uppsala University, the University of Turku, and the University of Bergen searched for a biomarker to facilitate determination of risk of the disease reoccurring.

The investigators used The Human Protein Atlas, to identify l-asparaginase (ASRGL1) as an endometrial carcinoma biomarker candidate. They then used a microarray immunohistochemical technique to evaluate ASRGL1 expression in samples collected from 500 women who had been diagnosed with uterine cancer between the years 1981 and 2007.

Results revealed that the ASRGL1 enzyme was highly expressed in normal endometrium and heterogeneously expressed in endometrial carcinoma. Patients with little or no ASRGL1 expression in their tumor cells were found to have a much higher risk of cancer recurrence or death, while patients with sustained high levels of ASRGL1 had a much lower risk of recurrence. ASRGL1 was found to be an independent prognostic factor, even after compensating for other risk factors such as tumor stage and tumor grade.

"I view the results as a first step towards personal treatment of uterine cancer. Today, 10-15% of the patients suffer recurrences, even though they were considered low risk patients according to classic diagnostics. By using ASRGL1, the chance of identifying such hidden high-risk patients and offer them more aggressive treatment after their operation increases," said first author Dr. Per-Henrik Edqvist, associate professor of immunology, genetics, and pathology at Uppsala University. "The Protein Atlas project enabled our discovery, and our study is an excellent example of how The Human Protein Atlas database can be used by researchers across the world to find interesting leads to follow up on."

The work was published in the April 6, 2017, online edition of the journal Gynecologic Oncology.


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
Serological Pipet Controller
PIPETBOY GENIUS
New
Celiac Disease Test
Anti-Gliadin IgG ELISA
New
Staining Management Software
DakoLink
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.